Trial Profile
EXtended Therapy in Genotype 3 Infected Patients Who do Not AChieve a Treatment Response at Week 4 (RVR) But do Achieve a Complete Early Virologic Response (cEVR).
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 01 Oct 2011
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms EXACT-R(3)
- 28 Sep 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Sep 2011 Planned end date changed from 1 Aug 2015 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 03 Apr 2010 New trial record